Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: B

Drug products: Cortimyk, Daktacort®, Daktar®, Mikonazol CCS

ATC code: D01AC02, D01AC20

Substances: miconazole, miconazole nitrate


A large amount of the studies consider treatment of vaginal infections, therefore analyses on sex or gender differences are lacking.
The present evidence concerning differences between men and women is very limited due to the indication of the substance but does not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

No difference between men and women has been shown for transdermal absorption in general [1].


No studies with a clinically relevant sex analysis regarding effects of mikonazol have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of mikonazol have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2017-02-21


  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21. PubMed
  2. Concise. Stockholm: eHälsomyndigheten. 2015 [cited 2017-03-02.] länk

Authors: Maria Enghag

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson